FAGR logo

Fagron NV Stock Price

ENXTBR:FAGR Community·€1.5b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author

FAGR Share Price Performance

€0
-18.38 (-100.00%)
€24.84
Fair Value
€0
-18.38 (-100.00%)
Price €0

FAGR Community Narratives

AnalystConsensusTarget·
Fair Value €24.84 18.3% undervalued intrinsic discount

APAC Expansion And Compounding Services Will Unlock Future Value

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative

Trending Discussion

Updated Narratives

FAGR logo

APAC Expansion And Compounding Services Will Unlock Future Value

Fair Value: €24.84 18.3% undervalued intrinsic discount
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with proven track record.

1 Risk
5 Rewards

Fagron NV Key Details

€918.8m

Revenue

€498.4m

Cost of Revenue

€420.3m

Gross Profit

€334.6m

Other Expenses

€85.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Feb 12, 2026
1.17
45.75%
9.33%
69.0%
View Full Analysis

About FAGR

Founded
1990
Employees
3989
CEO
Rafael Padilla
WebsiteView website
www.fagron.com

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Recent FAGR News & Updates

Fagron NV's (EBR:FAGR) Popularity With Investors Is Under Threat From Overpricing

Oct 29
Fagron NV's (EBR:FAGR) Popularity With Investors Is Under Threat From Overpricing

Recent updates

No updates